Outlook for 2024 Non-GAAP Results
| $ billions, except EPS or as noted | November 2024 Outlook | July 2024 Outlook | February 2024 Outlook |
| Revenues* | $16.1 - $16.5 | $16.0 - $16.4 | $15.7 - $16.3 |
| AUSTEDO ($m)* | ~1,600 | ~1,600 | ~1,500 |
| AJOVY ($m)* | ~500 | ~500 | ~500 |
| UZEDY ($m)* | ~100 | ~80 | ~80 |
| COPAXONE ($m)* | ~500 | ~450 | ~400 |
| Operating Income | 4.2 - 4.5 | 4.1 - 4.5 | 4.0 - 4.5 |
| Adjusted EBITDA | 4.7 - 5.0 | 4.6 - 5.0 | 4.5 - 5.0 |
| Finance Expenses ($m) | ~1,000 | ~1,000 | ~1,000 |
| Tax Rate | 14% - 17% | 14% - 17% | 14% - 17% |
| Diluted EPS ($) | 2.40 - 2.50 | 2.30 - 2.50 | 2.20 - 2.50 |
| Free Cash Flow** | 1.7 - 2.0 | 1.7 - 2.0 | 1.7 - 2.0 |
| CAPEX* | ~0.5 | ~0.5 | ~0.5 |
| Foreign Exchange | Volatile swings in FX can negatively impact revenue and income | ||
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。